The potential role of human multidrug resistance protein 1 (MDR1) and multidrug resistance-associated protein 2 (MRP2) in the transport of Huperzine A in vitro

References

• Aronica E, Gorter JA, Redeker S, et al. (2005). Localization of breast cancer resistance protein (BCRP) in microvessel endothelium of human control and epileptic brain. Epilepsia 46:849–57.
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Koepp MJ, et al. (2018). Progress report on new antiepileptic drugs: a summary of the fourteenth eilat conference on new antiepileptic drugs and devices (EILAT XIV). I. Drugs in preclinical and early clinical development. Epilepsia 59:1811–41.
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Levy RH, et al. (2015). Progress report on new antiepileptic drugs: a summary of the twelfth eilat conference (EILAT XII). Epilepsy Res 111:85–141.
   PubMed Web of Science ®Google Scholar
• Chan PS, Zhang C, Zuo Z, et al. (2014). In vitro transport assays of rufinamide, pregabalin, and zonisamide by human P-glycoprotein. Epilepsy Res 108:359–66.
   PubMed Web of Science ®Google Scholar
• Coleman BR, Ratcliffe RH, Oguntayo SA, et al. (2008). [+]-Huperzine A treatment protects against N-methyl-D-aspartate-induced seizure/status epilepticus in rats. Chem Biol Interact 175:387–95.
   PubMed Web of Science ®Google Scholar
• Damar U, Gersner R, Johnstone JT, et al. (2016). Huperzine A as a neuroprotective and antiepileptic drug: a review of preclinical research. Expert Rev Neurother 16:671–80.
   PubMed Web of Science ®Google Scholar
• Dinday MT, Baraban SC. (2015). Large-scale phenotype-based antiepileptic drug screening in a zebrafish model of dravet syndrome. eNeuro 2:pii: ENEURO.0068–15.
   Web of Science ®Google Scholar
• Gersner R, Ekstein D, Dhamne SC, et al. (2015). Huperzine A prophylaxis against pentylenetetrazole-induced seizures in rats is associated with increased cortical inhibition. Epilepsy Res 117:97–103.
   PubMed Web of Science ®Google Scholar
• Golyala A, Kwan P. (2017). Drug development for refractory epilepsy: the past 25 years and beyond. Seizure 44:147–56.
   PubMed Web of Science ®Google Scholar
• Grewal GK, Kukal S, Kanojia N, et al. (2017). Effect of oxidative stress on ABC transporters: contribution to epilepsy pharmacoresistance. Molecules 22:pii: E365.
   Web of Science ®Google Scholar
• Hoffmann K, Gastens AM, Volk HA, Löscher W. (2006). Expression of the multidrug transporter MRP2 in the blood-brain barrier after pilocarpine-induced seizures in rats. Epilepsy Res 69:1–14.
   PubMed Web of Science ®Google Scholar
• Jiang H, Luo X, Bai D. (2003). Progress in clinical, pharmacological, chemical and structural biological studies of huperzine A: a drug of traditional Chinese medicine origin for the treatment of Alzheimer’s disease. Curr Med Chem 10:2231–52.
   PubMed Web of Science ®Google Scholar
• Kim WJ, Lee JH, Yi J, et al. (2010). A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy. Pharmacogenet Genomics 20:249–56.
   PubMed Web of Science ®Google Scholar
• Kwan P, Brodie MJ. (2000). Early identification of refractory epilepsy. N Engl J Med 342:314–9.
   PubMed Web of Science ®Google Scholar
• Kwan P, Brodie MJ. (2005). Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia 46:224–35.
   PubMed Web of Science ®Google Scholar
• Kwan P, Li HM, Al-Jufairi E, et al. (2010). Association between temporal lobe P-glycoprotein expression and seizure recurrence after surgery for pharmacoresistant temporal lobe epilepsy. Neurobiol Dis 39:192–7.
   PubMed Web of Science ®Google Scholar
• Kwan P, Schachter SC, Brodie MJ. (2011). Drug-resistant epilepsy. N Engl J Med 365:919–26.
   PubMed Web of Science ®Google Scholar
• Lallement G, Baille V, Baubichon D, et al. (2002). Review of the value of huperzine as pretreatment of organophosphate poisoning. Neurotoxicology 23:1–5.
   PubMed Web of Science ®Google Scholar
• Li YX, Jiang XH, Lan K, Wang L. (2007). Simple determination of huperzine A in human plasma by liquid chromatographic-tandem mass spectrometric method. Biomed Chromatogr 21:15–20.
   PubMed Web of Science ®Google Scholar
• Li J, Yue M, Zhou D, et al. (2017). Abcb1a but not Abcg2 played a predominant role in limiting the brain distribution of Huperzine A in mice. Food Chem Toxicol 107:68–73.
   PubMed Web of Science ®Google Scholar
• Liu X, Yue X, Chen S, et al. (2015). Significance of the expression of MRP1 and MRP2 in peripheral blood mononuclear cells of children with intractable epilepsy. Exp Ther Med 10:1784–8.
   PubMed Web of Science ®Google Scholar
• Li J, Wu HM, Zhou RL, et al. (2008). Huperzine A for Alzheimer’s disease. Cochrane Database Syst Rev 2:CD005592. Available from: https://doi.org/10.1002/14651858.CD005592.pub2
   Google Scholar
• Loscher W, Klitgaard H, Twyman RE, Schmidt D. (2013). New avenues for anti-epileptic drug discovery and development. Nat Rev Drug Discov 12:757–76.
   PubMed Web of Science ®Google Scholar
• Loscher W, Potschka H. (2005). Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 6:591–602.
   PubMed Web of Science ®Google Scholar
• Luna-Tortós C, Rambeck B, Jürgens UH, Löscher W. (2009). The antiepileptic drug topiramate is a substrate for human P-glycoprotein but not multidrug resistance proteins. Pharm Res 26:2464–70.
   PubMed Web of Science ®Google Scholar
• Ma X, Tan C, Zhu D, et al. (2007). Huperzine A from Huperzia species-an ethnopharmacological review. J Ethnopharmacol 113:15–34.
   PubMed Web of Science ®Google Scholar
• Miller DS. (2015). Regulation of ABC transporters blood-brain barrier: the good, the bad, and the ugly. Adv Cancer Res 125:43–70.
   PubMed Web of Science ®Google Scholar
• Miller DS, Bauer B, Hartz AM. (2008). Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy. Pharmacol Rev 60:196–209.
   PubMed Web of Science ®Google Scholar
• Potschka H, Fedrowitz M, Loscher W. (2003a). Brain access and anticonvulsant efficacy of carbamazepine, lamotrigine, and felbamate in ABCC2/MRP2-deficient TR- rats. Epilepsia 44:1479–86.
   PubMed Web of Science ®Google Scholar
• Potschka H, Fedrowitz M, Loscher W. (2003b). Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity. J Pharmacol Exp Ther 306:124–31.
   PubMed Web of Science ®Google Scholar
• Schexnayder C, Stratford RE. (2015). Genistein and glyceollin effects on ABCC2 (MRP2) and ABCG2 (BCRP) in caco-2 cells. Int J Environ Res Public Health 13:17.
   Web of Science ®Google Scholar
• Schneider BM, Dodman NH, Faissler D, Ogata N. (2009). Clinical use of an herbal-derived compound (Huperzine A) to treat putative complex partial seizures in a dog. Epilepsy Behav 15:529–34.
   PubMed Web of Science ®Google Scholar
• van Hoppe S, Sparidans RW, Wagenaar E, et al. (2017). Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation. Pharmacol Res 120:43–50.
   PubMed Web of Science ®Google Scholar
• van Vliet EA, Redeker S, Aronica E, et al. (2005). Expression of multidrug transporters MRP1, MRP2, and BCRP shortly after status epilepticus, during the latent period, and in chronic epileptic rats. Epilepsia 46:1569–80.
   PubMed Web of Science ®Google Scholar
• Wambaugh JF, Hughes MF, Ring CL, et al. (2018). Evaluating in vitro-in vivo extrapolation of toxicokinetics. Toxicol Sci 163:152–69.
   PubMed Web of Science ®Google Scholar
• Wang R, Yan H, Tang XC. (2006). Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin 27:1–26.
   PubMed Web of Science ®Google Scholar
• Wong JC, Dutton SB, Collins SD, et al. (2016). Huperzine a provides robust and sustained protection against induced seizures in scn1a mutant mice. Front Pharmacol 7:357.
   PubMed Web of Science ®Google Scholar
• Xu SS, Gao ZX, Weng Z, et al. (1995). Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer’s disease. Zhongguo Yao Li Xue Bao 16:391–5.
   PubMed Web of Science ®Google Scholar
• Yang G, Wang Y, Tian J, Liu JP. (2013). Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials. PLoS One 8:e74916.
   PubMed Web of Science ®Google Scholar
• Yao D, Liu L, Jin S, et al. (2012). Overexpression of multidrug resistance-associated protein 2 in the brain of pentylenetetrazole-kindled rats. Neuroscience 227:283–92.
   PubMed Web of Science ®Google Scholar
• Ye JC, Zeng S, Zheng GL, Chen GS. (2008). Pharmacokinetics of Huperzine A after transdermal and oral administration in beagle dogs. Int J Pharm 356:187–92.
   PubMed Web of Science ®Google Scholar
• Yu D, Thakor DK, Han I, et al. (2013). Alleviation of chronic pain following rat spinal cord compression injury with multimodal actions of huperzine A. Proc Natl Acad Sci USA 110:E746–55.
   PubMed Web of Science ®Google Scholar
• Zhang C, Chanteux H, Zuo Z, et al. (2013). Potential role for human P-glycoprotein in the transport of lacosamide. Epilepsia 54:1154–60.
   PubMed Web of Science ®Google Scholar
• Zhang C, Kwan P, Zuo Z, Baum L. (2010). In vitro concentration dependent transport of phenytoin and phenobarbital, but not ethosuximide, by human P-glycoprotein. Life Sci 86:899–905.
   PubMed Web of Science ®Google Scholar
• Zhang C, Kwan P, Zuo Z, Baum L. (2012). The transport of antiepileptic drugs by P-glycoprotein. Adv Drug Deliv Rev 64:930–42.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Schuetz JD, Elmquist WF, Miller DW. (2004). Plasma membrane localization of multidrug resistance-associated protein homologs in brain capillary endothelial cells. J Pharmacol Exp Ther 311:449–55.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Wang X, Chen Q, et al. (2002). Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial. Zhonghua Yi Xue Za Zhi 82:941–4.
   PubMedGoogle Scholar
• Zhang C, Zuo Z, Kwan P, Baum L. (2011). In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein. Epilepsia 52:1894–904.
   PubMed Web of Science ®Google Scholar